Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that repurposes and reformulates already approved drugs for larger markets such as cystic fibrosis, recently announced that the United States Patent Office (USPO) has issued United States Patent No. 9029385 for its patent application, “Compositions and Methods for Treating Fibroproliferative Disorders.”…
News
According to a recent study published in the journal CHEST, the official journal of the American College of Chest Surgeons, several mortality-risk prediction models used in assessing mortality at 1-year in patients with idiopathic pulmonary fibrosis may also be a viable option in gauging short-term mortality in…
ProMetic Life Sciences Inc. recently validated the potential for its experimental drug target PBI-4050 to treat patients with idiopathic pulmonary fibrosis. Two presentations at the 2015 European Renal Association Annual Meeting identified that PBI-4050 reduces fibrosis in human cells. “Our data correlates the regulation activity of PBI-4050 on key fibrotic…
John McManus, Chief Executive Officer, presented an outline of Aeolus’ development programs with a focus on the company’s progress regarding its contract with the Biomedical Advanced Research and Development Authority (“BARDA”), during the LD Micro Invitational meeting that took place last December in Los Angeles. The details of that meeting were recently…
Building a new set of lungs for patients with pulmonary fibrosis is becoming closer to reality as a result of cutting-edge research in the field of tissue engineering. At the forefront of this endeavor is Cheryl Nickerson, PhD, an expert in infectious diseases and vaccinology at Arizona State University Biodesign Institute.
RestorGenex Pharmaceuticals, a biotechnology company developing innovative therapeutics for a large spectrum of diseases, including cancer and those of the dermatology and ophthalmology spectrum, recently presented at the American Thoracic Society International Conference in Denver, Colorado their latest results using RES-529 as a potential treatment for idiopathic pulmonary fibrosis.
Veracyte, Inc. a biotechnology company working in the field of molecular cytology, recently presented new results showing that its molecular classifier can distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) in bronchoscopy-derived samples. The results indicate that the molecular classifier is able to help patients avoid invasive,…
During the 2015 American Thoracic Society Conference (ATS), Genentech presented new data on Esbriet (pirfenidone) — one of the first medicines approved by the US Food and Drug Administration to treat idiopathic pulmonary fibrosis (IPF), a serious disease of unknown origins that causes permanent scarring of the lungs.
Boehringer Ingelheim recently announced positive results regarding the safety, tolerability and efficacy of FDA-approved OFEV® (nintedanib*) in patients with idiopathic pulmonary fibrosis (IPF). The results were recently presented during the 2015 International Conference of the American Thoracic Society (ATS), which took place in Denver, and reveal continued long-term effectiveness in…
The Hastings Foundation has announced that it is going to grant $7.5 million in support to the University of South California (USC) for the creation of the Hastings Center for Pulmonary Research (HCPR) at Keck Medicine of USC. The grant will be spread across five years with the main purpose on improving research…
